SCHEMBL4756265

SCHEMBL4756265

CC(=O)Nc1ccc([C]=O)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.59
CYP1A2 P05177 1/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.48
KMT2A Q03164 3/20 0.46
RAB9A P51151 2/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 2/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
NSD2 O96028 1/20 0.43
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
TDO2 P48775 1/20 0.41
TMPRSS4 Q9NRS4 1/20 0.39
GLS O94925 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1430551 0.84 KMT2A (0.57) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL4104898 0.84 PTK2 (0.57) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL7342553 0.77 RAB9A (0.47) GAAL3MBTL1KMT2ARAB9AMAPT
SCHEMBL6844742 0.77 PTK2 (0.49) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL2646127 0.76 PTK2 (0.65) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL423961 0.76 RAB9A (0.75) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL4757589 0.76 L3MBTL1 (0.44) PTK2CYP1A2GAAL3MBTL1KMT2A
SCHEMBL1977386 0.76 PTK2 (0.65) PTK2CYP1A2GAAKMT2AMAPT
SCHEMBL1430301 0.74 PTK2 (0.62) PTK2CYP1A2GAAKMT2ARAB9A
SCHEMBL14223704 0.74 PTK2 (0.62) PTK2CYP1A2GAAL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO claimed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US claimed
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO disclosed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275085-A1 Piperidine derivative and use thereof TACR2, TACR1, PRLHR PTK2 1754/4885CYP1A2 4132/4885GAA 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.